Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Finished Goods: 2022-2025

Historic Finished Goods for Fennec Pharmaceuticals (FENC) over the last 3 years, with Sep 2025 value amounting to $2.5 million.

  • Fennec Pharmaceuticals' Finished Goods rose 120.18% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 million, marking a year-over-year increase of 120.18%. This contributed to the annual value of $1.1 million for FY2024, which is 50.83% down from last year.
  • Latest data reveals that Fennec Pharmaceuticals reported Finished Goods of $2.5 million as of Q3 2025, which was up 12.54% from $2.2 million recorded in Q2 2025.
  • Over the past 5 years, Fennec Pharmaceuticals' Finished Goods peaked at $2.5 million during Q3 2025, and registered a low of $576,000 during Q4 2022.
  • Its 3-year average for Finished Goods is $1.7 million, with a median of $1.8 million in 2023.
  • In the last 5 years, Fennec Pharmaceuticals' Finished Goods skyrocketed by 274.31% in 2023 and then plummeted by 50.83% in 2024.
  • Over the past 4 years, Fennec Pharmaceuticals' Finished Goods (Quarterly) stood at $576,000 in 2022, then spiked by 274.31% to $2.2 million in 2023, then plummeted by 50.83% to $1.1 million in 2024, then spiked by 120.18% to $2.5 million in 2025.
  • Its Finished Goods was $2.5 million in Q3 2025, compared to $2.2 million in Q2 2025 and $1.4 million in Q1 2025.